Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.

J Pathol. 2007 May;212(1):91-101.

2.

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927. Epub 2009 Jul 7.

3.
4.
5.

TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.

Barry M, Perner S, Demichelis F, Rubin MA.

Urology. 2007 Oct;70(4):630-3.

6.

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, Rubin MA.

Neoplasia. 2007 Mar;9(3):200-6.

7.

TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.

Dong J, Xiao L, Sheng L, Xu J, Sun ZQ.

Asian Pac J Cancer Prev. 2014;15(7):3099-103.

8.

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.

Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6.

9.

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.

Neoplasia. 2006 Oct;8(10):885-8.

10.

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.

Mod Pathol. 2010 Nov;23(11):1499-506. doi: 10.1038/modpathol.2010.150. Epub 2010 Aug 6.

11.

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.

Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.

Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20.

PMID:
22821767
12.

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group.

Oncogene. 2008 Jan 10;27(3):253-63. Epub 2007 Jul 16.

13.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004. Epub 2013 Jan 24.

14.

Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.

Fleischmann A, Saramäki OR, Zlobec I, Rotzer D, Genitsch V, Seiler R, Visakorpi T, Thalmann GN.

Prostate. 2014 Dec;74(16):1647-54. doi: 10.1002/pros.22882. Epub 2014 Sep 22.

PMID:
25252136
15.

Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.

Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.

Mod Pathol. 2007 May;20(5):538-44. Epub 2007 Mar 2.

16.

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M.

Prostate. 2011 Apr;71(5):489-97. doi: 10.1002/pros.21265. Epub 2010 Sep 28.

PMID:
20878952
17.

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.

Cancer Res. 2009 Feb 15;69(4):1400-6. doi: 10.1158/0008-5472.CAN-08-2467. Epub 2009 Feb 3.

18.

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.

Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O.

Cancer Res. 2006 Nov 1;66(21):10242-6.

19.

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

Neoplasia. 2009 Aug;11(8):804-11.

20.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468

Supplemental Content

Support Center